Pinned straw:
Here's a link from Tim Boreham to balance out the arguments in my initial post. Old link though:
Also from latest slide they are aiming for 240K Technegas procedures in the US which equates to $US36m revenue and then hitting 600K in year 5 (US$150 per procedure).
Conservatively I think it will be half of that or $18m which reiterates the point they won't be profitable unless they can reign in the expenses such as Sales/GA (but I hope I'm wrong!)
Another point I need to clarify is the latest annual report does not clarify any indirect costs related to the FDA approval expense. So it is likely they may have been breakeven without the US FDA distraction.
An unusual observation that it is rather "odd" Technegas profitability is geared towards the US launch.
I did register for the Zoom call in the hope of viewing the recording but that they have denied access by changing the passcode which is annoying.
Going to email them.